Allos Therapeutics` CEO Stephen Hoffman talks to The Wall Street Transcript
...By increasing tumor oxygenation, RSR13 has the potential to enhance the efficacy of standard radiation therapy.......Allos is currently conducting a pivotal Phase III trial for the treatment of metastatic brain tumors....
Oct 03 11:28 AM ET
Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)
Posted on: 10/03/2001
"Yahoo - Allos Therapeutics' CEO Stephen Hoffman talks to The Wall Street Transcript"
[ Latest Headlines
News Alerts ]
Wednesday October 3, 11:28 am Eastern Time
Press ReleaseSOURCE: Allos Therapeutics, Inc.
Allos Therapeutics' CEO Stephen Hoffman talks to The Wall Street Transcript
NEW YORK--(BUSINESS WIRE)--Oct. 3, 2001--The Wall Street
Transcript has published an in-depth interview with Dr. Stephen
Hoffman, CEO of Allos Therapeutics (Nasdaq:ALTH - news), in which he talks at
length about the company's future.
The entire 2,000-word interview is available free online at
Hoffman gives an overview of the company. "Allos Therapeutics has
been in operation since 1994. We are focused on developing a new class
of pharmaceutical compounds described as synthetic allosteric
modifiers. The first product we have in clinical development from this
new class of agents is designated RSR13. RSR13 has a unique mechanism
of action that increases the release of oxygen from hemoglobin, the
oxygen carrying protein contained within red blood cells. By
increasing tumor oxygenation, RSR13 has the potential to enhance the
efficacy of standard radiation therapy. Allos is currently conducting
a pivotal Phase III trial for the treatment of metastatic brain
tumors. We expect to complete enrollment in this pivotal, Phase III
clinical trial in approximately 12-15 months."
Hoffman explains, Allos is the only company developing a drug that
increases the amount of oxygen in the tumor to increase the
effectiveness of therapy. Oxygen is a required component of radiation
therapy -- without sufficient levels in the tumor, radiation isn't
effective. There are a couple of other companies developing radiation
sensitizers that have less clear mechanisms of action."
Looking forward, Hoffman states, "By 2005, we would certainly hope
to have RSR13 on the market as a radiation sensitizing agent in North
America and on the market in Europe for our lead treatment indication
of treating metastatic brain tumors. Also by that time, we would have
completed a number of label expansion studies showing proof of
principle for the effectiveness of RSR13 in treating other types of
malignant tumors, for example, in the treatment of primary lung
cancer, primary brain cancer, cervical cancer and other tumors that
collectively result in 750,000 patients receiving radiation therapy
per year in the US alone."
This interview is part of a 179-page Biotechnology Issue available
at http://www.twst.com/info/info423.htm or by calling 212/952-7433
The Wall Street Transcript does not endorse the views of any
interviewees nor does it make stock recommendations. For subscription
information call 800/246-7673.
Allos Therapeutics, Inc.
Monique Greer, 303/426-6262
Email this story - Most-emailed articles - Most-viewed articles
Copyright © 2001 Yahoo! Inc. All rights reserved.
Terms of Service
Copyright © 2001 Business
All rights reserved. All the news releases provided
Business Wire are copyrighted. Any forms of copying
other than an
individual user's personal reference without express
permission is prohibited. Further distribution of these
posting, archiving in a public web site or database
in a computer network is strictly forbidden.
Questions or Comments?
Click HERE to return to brain tumor news headlines